Growth funding KdT Ventures recently closed its fourth fund with over $100M to back early-stage, science-driven companies, indicating a strong appetite for new investments and potential co-investment or fundraising discussions with portfolio companies that align with their thesis.

Portfolio expansion Recent news highlights formation of a new company around NGM313 for a rare disease indication, suggesting opportunities to approach KdT with additional rare disease or technology-enabled biotech ventures that could fit their focus on the intersection of technology and science.

Leadership growth Promotions of Dr. Phil Grayeski to managing partner and Patrick Malone to partner signal a leadership expansion in their investment and decision-making capacities, which can open doors for higher-touch outreach and strategic co-investment conversations.

Active exits and wins Historical investments in early-stage health and tech companies (e.g., Marigold Health, Aperiam Bio) show a track record of backing science-driven startups, suggesting potential fit for founders seeking seed-to-early-stage funding, mentorship, and strategic introductions.

Tech-enabled value Their tech stack and emphasis on compute-enabled problem solving indicate a preference for startups leveraging computational approaches, data, or digital platforms, presenting a target angle for outreach to founders with AI, data science, or software-enabled science solutions seeking seed funding.